Short description
Aerpio Pharmaceuticals is a biotechnology company that develops small molecules and monoclonal antibodies for vascular diseases treatment.
Description
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.
Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States.
Last funding
No Way
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Cincinnati, Ohio, United States, North America
Founded on
January 1, 2011
Exited on
February 2, 2018
Went public on
February 2, 2018
Stock symbol
ARPO
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccess, Noaccess, Uh Ohhhh, Nopepepe, Noaccess, Uh Ohhhh, Noaccessforu, Noway Youcantaccess, Uh Ohhhh, Noway Youcantaccess, Uh Ohhhh
Sign in for full access
Founders
Joseph Gardner, Robert Shalwitz